Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 120Gastrointestinal 92Dermatologic 81Genitourinary 69Head & Neck 65Breast 53Gynecologic 48Other solid neoplasm 41Lymphoid 27Tumor-Agnostic 18Sarcoma 18CNS 17Plasma cell 8Other hematologic neoplasm 7Endocrine 3NET 2Myeloid 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Small Cell 1

Interventions

lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 3surufatinib 2pembrolizumab 2olaparib 2lanreotide 2atezolizumab 2Everolimus 23-Iodobenzylguanidine 2tivozanib 1tislelizumab 1repotrectinib 1regorafenib 1pralsetinib 1irinotecan sucrosofate 1cabozantinib 1avelumab 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1Tirapazamine 1Temozolomide 1TKM-080301 1S 1 (combination) 1Radiotherapy 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1PM 01183 1Ondansetron 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × pembrolizumab × NET × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT03043664 2023-06-29

PLANET

Duke University

Phase 1/2 Completed
22 enrolled 12 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡